TABLE 3.
Outcome | N studies | MD [95% CI] or SMD [95% CI] | P value | I2 ‐ Tau2 (P value) | [95% PI] |
---|---|---|---|---|---|
Effect observed after the intervention | |||||
Change in body weight | 14 | MD: −1.8 [−3.2; −0.4] kg | 0.01 | 35% ‐ 2.28 (0.09) | [−5.4; 1.8] |
Change in fat mass | 9 | MD: −2.1 [−3.7; −0.5] kg | 0.01 | 50% ‐ 2.76 (0.04) | |
Change in lean body mass | 11 | MD: 0.7 [−0.2; 1.6] kg | 0.13 | 45% ‐ 0.92 (0.05) | [−1.7; 3.1] |
Change in bone mineral density | 3 | SMD: 0.44 [0.21; 0.67] | 0.0002 | 0% ‐ 0.0 (0.40) | |
Change in VO2max | 8 | SMD: 0.70 [0.35; 1.10] | <0.0001 | 42% ‐ 0.10 (0.10) | |
Change in muscle strength | 9 | SMD: 0.82 [0.48; 1.16] | <0.0001 | 42% ‐ 0.11 (0.09) | |
Change in walking distance | 6 | SMD: 1.46 [0.27; 2.66] | 0.02 | 90% ‐ 1.98 (<0.001) | |
Systolic blood pressure | 4 | MD: −4.2 [−9.3; 1.0] mmHg | 0.12 | 47% ‐ 12.7 (0.13) | |
Diastolic blood pressure | 4 | MD: −2.3 [−8.5; 3.9] mmHg | 0.47 | 77% ‐ 29.1 (0.005) | |
HOMA‐IR | 2 | SMD: 0.14 [−0.10; 0.38] | 0.27 | 0% ‐ 0.0 (0.49) | |
LDL‐c | 3 | SMD: −0.18 [−0.46; 0.09] | 0.20 | 0% ‐ 0.0 (0.59) | |
HDL‐c | 4 | SMD: 0.10 [−0.16; 0.37] | 0.45 | 0% ‐ 0.0 (0.51) | |
Triglycerides | 4 | SMD: 0.01 [−0.26; 0.27] | 0.97 | 0% ‐ 0.0 (0.88) | |
Quality of life—physical dimension | 2 | MD: −2.5 [−5.1; 0.2] | 0.07 | 0% ‐ 0.0 (0.32) | |
Quality of life—mental dimension | 2 | MD: 3.9 [−0.5; 8.3] | 0.08 | 0% ‐ 0.0 (0.37) | |
Effect observed after a follow‐up without exercisea | |||||
Change in body weight | 2 | MD: −4.7 [−7.2; −2.1] kg | 0.0003 | 0% ‐ 0.0 (0.49) | |
Change in muscle strength | 2 | SMD: 0.78 [−0.08; 1.64] | 0.08 | 57% ‐ 0.23 (0.13) |
Note: 95% PI: 95% prediction intervals. 95% PI were calculated when the number of studies included in the meta‐analysis was ≥10 for a given outcome.
Abbreviations: HDL‐c, high‐density lipoprotein cholesterol; HOMA‐IR, homeostatic model assessment of insulin resistance; LDL‐c, low‐density lipoprotein cholesterol; MD, mean difference; PI, prediction interval; SMD, standardized mean difference.